200 related articles for article (PubMed ID: 1282624)
1. Bradykinin degrading activity in cultured human endothelial cells.
Graf K; Gräfe M; Auch-Schwelk W; Baumgarten CR; Bossaller C; Fleck E
J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S16-20. PubMed ID: 1282624
[TBL] [Abstract][Full Text] [Related]
2. Endothelial angiotensin-converting enzyme and neutral endopeptidase in isolated human umbilical vein: an effective bradykinin inactivation pathway.
Nowak W; Errasti AE; Armesto AR; Santín Velazque NL; Rothlin RP
Eur J Pharmacol; 2011 Sep; 667(1-3):271-7. PubMed ID: 21651905
[TBL] [Abstract][Full Text] [Related]
3. Contributions of various rat plasma peptidases to kinin hydrolysis.
Ishida H; Scicli AG; Carretero OA
J Pharmacol Exp Ther; 1989 Dec; 251(3):817-20. PubMed ID: 2557417
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of vasoactive peptides by human endothelial cells in culture. Angiotensin I converting enzyme (kininase II) and angiotensinase.
Johnson AR; Erdös EG
J Clin Invest; 1977 Apr; 59(4):684-95. PubMed ID: 191471
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries.
Sivieri DO; Bispo-da-Silva LB; Oliveira EB; Resende AC; Salgado MC
Hypertension; 2007 Jul; 50(1):110-5. PubMed ID: 17470724
[TBL] [Abstract][Full Text] [Related]
6. Role of ACE and NEP in bradykinin-induced relaxation and contraction response of isolated porcine basilar artery.
Miyamoto A; Murata S; Nishio A
Naunyn Schmiedebergs Arch Pharmacol; 2002 May; 365(5):365-70. PubMed ID: 12012022
[TBL] [Abstract][Full Text] [Related]
7. Degradation of bradykinin by neutral endopeptidase (EC 3.4.24.11) in cultured human endothelial cells.
Graf K; Gräfe M; Bossaller C; Niehus J; Schulz KD; Auch-Schwelk W; Fleck E
Eur J Clin Chem Clin Biochem; 1993 May; 31(5):267-72. PubMed ID: 8395230
[TBL] [Abstract][Full Text] [Related]
8. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
[TBL] [Abstract][Full Text] [Related]
9. Kininase II-type enzymes. Their putative role in muscle energy metabolism.
Dragović T; Minshall R; Jackman HL; Wang LX; Erdös EG
Diabetes; 1996 Jan; 45 Suppl 1():S34-7. PubMed ID: 8529798
[TBL] [Abstract][Full Text] [Related]
10. Possible involvement of placental proteases in bradykinin (BK) degradation.
Kuno N; Mizutani S; Ohno Y; Goto K; Itakura A; Kondo I; Kurauchi O; Kikkawa F; Tomoda Y
Reprod Fertil Dev; 1997; 9(6):633-9. PubMed ID: 9551668
[TBL] [Abstract][Full Text] [Related]
11. Lipopolysaccharides decrease angiotensin converting enzyme activity expressed by cultured human endothelial cells.
Watanabe K; Lam G; Keresztes RS; Jaffe EA
J Cell Physiol; 1992 Feb; 150(2):433-9. PubMed ID: 1310327
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone induced enhanced enkephalin degradation by angiotensin-converting enzyme (ACE) of endothelial cells.
Melzig MF; Heder G
Pharmazie; 1995 Feb; 50(2):139-41. PubMed ID: 7700968
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells.
Kohlstedt K; Brandes RP; Müller-Esterl W; Busse R; Fleming I
Circ Res; 2004 Jan; 94(1):60-7. PubMed ID: 14615289
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies.
Skidgel RA; Erdös EG
Peptides; 2004 Mar; 25(3):521-5. PubMed ID: 15134871
[TBL] [Abstract][Full Text] [Related]
15. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
[TBL] [Abstract][Full Text] [Related]
16. Altered cardiac bradykinin metabolism in experimental diabetes caused by the variations of angiotensin-converting enzyme and other peptidases.
Adam A; Leclair P; Montpas N; Koumbadinga GA; Bachelard H; Marceau F
Neuropeptides; 2010 Apr; 44(2):69-75. PubMed ID: 19836835
[TBL] [Abstract][Full Text] [Related]
17. A ligand-based approach to investigate the expression and function of angiotensin converting enzyme in intact human umbilical vein endothelial cells.
Koumbadinga GA; Bawolak MT; Marceau E; Adam A; Gera L; Marceau F
Peptides; 2010 Aug; 31(8):1546-54. PubMed ID: 20452384
[TBL] [Abstract][Full Text] [Related]
18. Endothelium-derived bradykinin: implications for angiotensin-converting enzyme-inhibitor therapy.
Busse R; Fleming I; Hecker M
J Cardiovasc Pharmacol; 1993; 22 Suppl 5():S31-6. PubMed ID: 7508049
[TBL] [Abstract][Full Text] [Related]
19. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
Sulpizio AC; Pullen MA; Edwards RM; Brooks DP
J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834
[TBL] [Abstract][Full Text] [Related]
20. The novel gaseous vasorelaxant hydrogen sulfide inhibits angiotensin-converting enzyme activity of endothelial cells.
Laggner H; Hermann M; Esterbauer H; Muellner MK; Exner M; Gmeiner BM; Kapiotis S
J Hypertens; 2007 Oct; 25(10):2100-4. PubMed ID: 17885553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
